MX2021013472A - Moduladores de thr-? y metodos de uso de estos. - Google Patents
Moduladores de thr-? y metodos de uso de estos.Info
- Publication number
- MX2021013472A MX2021013472A MX2021013472A MX2021013472A MX2021013472A MX 2021013472 A MX2021013472 A MX 2021013472A MX 2021013472 A MX2021013472 A MX 2021013472A MX 2021013472 A MX2021013472 A MX 2021013472A MX 2021013472 A MX2021013472 A MX 2021013472A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- moiety
- methods
- thr
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente se divulgan compuestos de la Fórmula I: (I) TL-La-CE-HD o una sal, profármaco, amida o éster aceptable desde el punto de vista farmacéutico de estos, donde i) TL es una porción de la Fórmula IIa, IIb, IIIa, IIIb, IIIc o IIId; ii) CE es una porción de la Fórmula IV; iii) HD es una porción de la Fórmula V o VI; donde los sustituyentes son como se definen en la presente. También se divulgan composiciones farmacéuticas que comprenden los compuestos anteriores y métodos para tratar enfermedades mediante la administración o el contacto de un paciente con uno o más de los compuestos anteriores. (ver Fórmulas).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845252P | 2019-05-08 | 2019-05-08 | |
| US201962944052P | 2019-12-05 | 2019-12-05 | |
| US202063005661P | 2020-04-06 | 2020-04-06 | |
| PCT/US2020/031904 WO2020227549A1 (en) | 2019-05-08 | 2020-05-07 | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013472A true MX2021013472A (es) | 2022-01-06 |
Family
ID=70919081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013472A MX2021013472A (es) | 2019-05-08 | 2020-05-07 | Moduladores de thr-? y metodos de uso de estos. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11091467B2 (es) |
| EP (2) | EP3965884B1 (es) |
| JP (2) | JP7574223B2 (es) |
| KR (1) | KR20220017917A (es) |
| CN (1) | CN114096531A (es) |
| AU (1) | AU2020267576B2 (es) |
| BR (1) | BR112021021718A2 (es) |
| CA (1) | CA3139101A1 (es) |
| CL (1) | CL2021002883A1 (es) |
| CO (1) | CO2021015698A2 (es) |
| DK (1) | DK3965884T3 (es) |
| ES (1) | ES3020290T3 (es) |
| FI (1) | FI3965884T3 (es) |
| GE (1) | GEP20247637B (es) |
| HR (1) | HRP20250384T1 (es) |
| HU (1) | HUE070650T2 (es) |
| IL (1) | IL287720A (es) |
| LT (1) | LT3965884T (es) |
| MA (1) | MA55890B1 (es) |
| MD (1) | MD3965884T2 (es) |
| MX (1) | MX2021013472A (es) |
| PE (1) | PE20220255A1 (es) |
| PH (1) | PH12021552782A1 (es) |
| PL (1) | PL3965884T3 (es) |
| PT (1) | PT3965884T (es) |
| RS (1) | RS66686B1 (es) |
| SG (1) | SG11202111552YA (es) |
| SI (1) | SI3965884T1 (es) |
| TW (1) | TWI855068B (es) |
| WO (1) | WO2020227549A1 (es) |
| ZA (1) | ZA202409114B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| CN114430743A (zh) * | 2019-08-23 | 2022-05-03 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
| CN113454069B (zh) * | 2019-11-26 | 2025-03-14 | 昆药集团股份有限公司 | 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用 |
| CN114787153A (zh) * | 2019-12-26 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CN113278013B (zh) * | 2020-02-20 | 2022-09-23 | 昆药集团股份有限公司 | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 |
| CA3185710A1 (en) * | 2020-06-02 | 2021-12-09 | Chengdu Kanghong Pharmaceutical Co., Ltd. | Novel thyroid hormone .beta. receptor agonist |
| WO2022053028A1 (zh) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用 |
| JP2023541870A (ja) * | 2020-09-10 | 2023-10-04 | ▲蘇▼州科睿思制▲葯▼有限公司 | レスメチロム（ｒｅｓｍｅｔｉｒｏｍ）の結晶形態、その調製方法、及びその使用について |
| US20240025875A1 (en) * | 2020-09-17 | 2024-01-25 | Sunshine Lake Pharma Co., Ltd. | A compound as a thyroid hormone beta receptor agonist and use thereof |
| KR20230123929A (ko) * | 2020-11-06 | 2023-08-24 | 알리고스 테라퓨틱스 인코포레이티드 | 갑상선 수용체 작용제로서의 피리다지논 유도체 및 이의 용도 |
| WO2022099066A1 (en) * | 2020-11-06 | 2022-05-12 | Aligos Therapeutics, Inc. | Oxindoles and methods of use thereof |
| CN114591300A (zh) * | 2020-12-04 | 2022-06-07 | 南京圣和药业股份有限公司 | 作为THRβ激动剂的杂环化合物及其应用 |
| CN112645936B (zh) * | 2020-12-17 | 2022-03-01 | 山东第一医科大学(山东省医学科学院) | 取代的哒嗪酮类化合物及其用途 |
| CN114685450A (zh) * | 2020-12-30 | 2022-07-01 | 昆药集团股份有限公司 | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| BR112023017612A2 (pt) * | 2021-03-03 | 2023-12-05 | Terns Pharmaceuticals Inc | Compostos agonistas do receptor beta do hormônio da tireoide |
| KR20240018414A (ko) * | 2021-03-04 | 2024-02-13 | 후캉 (상하이) 헬스 테크놀로지 씨오 엘티디 | 방향족 화합물, 그 제조 방법 및 적용 |
| CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法 |
| WO2022242743A1 (zh) * | 2021-05-21 | 2022-11-24 | 深圳微芯生物科技股份有限公司 | 一种杂环化合物及其应用 |
| WO2023023474A1 (en) * | 2021-08-16 | 2023-02-23 | Senya Pharmaceuticals, Inc. | Tr-beta modulators, pharmaceutical compositions, and therapeutic applications |
| CA3230222A1 (en) | 2021-09-01 | 2023-03-09 | Leonid Beigelman | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| JP2024533262A (ja) | 2021-09-08 | 2024-09-12 | アリゴス セラピューティクス，インコーポレーテッド | 修飾された短鎖干渉核酸（ｓｉｎａ）分子及びその使用 |
| CN116354934A (zh) * | 2021-12-28 | 2023-06-30 | 中国科学院上海药物研究所 | 一类喹啉类化合物及其制备方法、药物组合物和用途 |
| CN115650928B (zh) * | 2022-12-28 | 2023-03-31 | 凯思凯旭(上海)医药科技有限公司 | 一种多环类甲状腺激素β受体激动剂及其用途 |
| WO2024182446A2 (en) | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| WO2024187038A1 (en) | 2023-03-07 | 2024-09-12 | Aligos Therapeutics, Inc. | Modified short inerfering nucleic acid (sina) molecules and uses thereof |
| WO2024260309A1 (zh) * | 2023-06-19 | 2024-12-26 | 西威埃医药技术（上海）有限公司 | THR-β受体激动剂、其制备方法和其使用方法 |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| CN117327057A (zh) * | 2023-08-30 | 2024-01-02 | 南京雷正医药科技有限公司 | 一类作为甲状腺激素受体激动剂的三嗪二酮类化合物及其合成、用途 |
| WO2025137568A1 (en) * | 2023-12-21 | 2025-06-26 | Aligos Therapeutics, Inc. | Modulators of thr-beta and methods of use thereof |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| DK1088819T3 (da) * | 1999-09-30 | 2005-09-12 | Pfizer Prod Inc | 6-azauracilderivater som thyroidreceptorligander |
| GB0015205D0 (en) | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
| EP1262177B1 (en) | 2001-05-31 | 2006-08-23 | Pfizer Products Inc. | Medical use of thyromimetic compounds to treat hair loss and compositions |
| WO2003064369A1 (fr) | 2002-01-30 | 2003-08-07 | Kissei Pharmaceutical Co., Ltd. | Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation |
| MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
| AU2003278544A1 (en) | 2002-11-25 | 2004-06-18 | Pfizer Products Inc. | Method for promoting nail growth using thyromimetic compounds |
| AU2006271721C1 (en) * | 2005-07-21 | 2013-09-19 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives as thyroid hormone receptor agonists |
| CN101426777A (zh) * | 2005-12-21 | 2009-05-06 | 先灵公司 | 用作组胺h3拮抗剂的苯氧基哌啶及其类似物 |
| AU2007265940A1 (en) * | 2006-06-28 | 2008-01-03 | Sanwa Kagaku Kenkyusho Co., Ltd. | Novel 6-5 System Bicyclic Heterocyclic Derivative And Its Pharmaceutical Utility |
| WO2008104752A1 (en) * | 2007-02-26 | 2008-09-04 | Astrazeneca Ab | Dihydropyridones as elastase inhibitors |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| WO2010122980A1 (ja) | 2009-04-20 | 2010-10-28 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
| JP5847533B2 (ja) | 2010-10-19 | 2016-01-27 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
| EP2695611B1 (en) | 2012-08-06 | 2014-10-01 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof |
| EP3689853B1 (en) * | 2012-09-17 | 2021-11-24 | Madrigal Pharmaceuticals, Inc. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| EP3019196B1 (en) | 2013-07-09 | 2018-06-06 | Bristol-Myers Squibb Company | Combinations of hepatitis c virus inhibitors |
| US10303567B2 (en) | 2013-08-15 | 2019-05-28 | Entit Software Llc | Managing database nodes |
| GB201318793D0 (en) | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
| EA201791258A1 (ru) | 2015-01-09 | 2017-12-29 | Джилид Аполло, Ллс | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени |
| CN115154467B (zh) | 2016-06-03 | 2024-08-23 | 坎莫森特里克斯公司 | 治疗肝纤维化的方法 |
| KR20190109387A (ko) | 2016-10-18 | 2019-09-25 | 마드리갈 파마슈티칼스, 인크. | Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법 |
| AU2018233975A1 (en) | 2017-03-13 | 2019-09-12 | Genfit | Pharmaceutical compositions for combination therapy |
| KR102699958B1 (ko) | 2017-04-18 | 2024-08-29 | 장피트 | 엘라피브라노르와 같은 ppar 작용제 및 아세틸-coa 카르복실라아제 (acc) 저해제를 포함하는 조합 |
| US10857144B2 (en) | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| CN111183360B (zh) | 2017-07-19 | 2024-10-18 | 生物辐射欧洲有限公司 | 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合 |
| WO2019099457A1 (en) | 2017-11-14 | 2019-05-23 | Quixgen, Inc. | Benzodioxinone compounds |
| ES2996688T3 (en) | 2017-12-06 | 2025-02-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| CN111646979B (zh) | 2018-01-23 | 2021-08-31 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| US20210008020A1 (en) | 2018-03-12 | 2021-01-14 | Yale University | Methods of Treating or Preventing Acute Respiratory Distress Syndrome |
| US11931345B2 (en) | 2018-05-04 | 2024-03-19 | Cirius Therapeutics, Inc. | Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases |
| CN108727344A (zh) | 2018-05-14 | 2018-11-02 | 嘉兴特科罗生物科技有限公司 | 一种化合物及其合成方法和应用 |
| PT3807267T (pt) | 2018-06-12 | 2025-05-22 | Xizang Haisco Pharmaceutical Co Ltd | Agonistas do recetor da hormona da tiroide e usos dos mesmos |
| EP3806832A1 (en) | 2018-06-14 | 2021-04-21 | Alma Mater Studiorum - Università di Bologna | Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug |
| CN110627773B (zh) | 2018-06-22 | 2021-03-19 | 海创药业股份有限公司 | 氘代mgl-3196化合物及其用途 |
| TW202019914A (zh) | 2018-07-02 | 2020-06-01 | 美商瑪德瑞高製藥公司 | ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式 |
| TWI825144B (zh) | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
| WO2020041741A1 (en) | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN119552152A (zh) * | 2018-10-12 | 2025-03-04 | 益方生物科技(上海)股份有限公司 | 甲状腺激素受体激动剂 |
| TWI840423B (zh) | 2018-10-12 | 2024-05-01 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020169069A1 (en) | 2019-02-21 | 2020-08-27 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
| WO2020227549A1 (en) * | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| TW202108556A (zh) | 2019-05-10 | 2021-03-01 | 大陸商深圳微芯生物科技股份有限公司 | 一種噠嗪酮衍生物及其應用 |
| IT201900006923A1 (it) | 2019-05-16 | 2020-11-16 | International Soc For Drug Development S R L | Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso |
| CN114174282A (zh) | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| TW202115029A (zh) | 2019-07-31 | 2021-04-16 | 大陸商深圳微芯生物科技股份有限公司 | 雜環化合物及其用途 |
| US20220298187A1 (en) | 2019-08-19 | 2022-09-22 | Hepagene Therapeutics (HK) Limited | Heterocyclic thr-b receptor agonist compound and preparation method and use therefor |
| CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
| CN114430743A (zh) | 2019-08-23 | 2022-05-03 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
| WO2021043185A1 (en) | 2019-09-04 | 2021-03-11 | Sunshine Lake Pharma Co., Ltd. | A compound as a thyroid hormone beta receptor agonist and use thereof |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021057791A1 (zh) | 2019-09-24 | 2021-04-01 | 广东东阳光药业有限公司 | 一种作为甲状腺激素Beta受体激动剂的化合物及其用途 |
| CN112707892A (zh) | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
| CN113454069B (zh) | 2019-11-26 | 2025-03-14 | 昆药集团股份有限公司 | 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用 |
| JP2023510835A (ja) | 2020-01-13 | 2023-03-15 | エコジーン （シャンハイ） カンパニー リミテッド | 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン |
| WO2021204577A1 (en) | 2020-04-06 | 2021-10-14 | Basf Se | Imidazo-pyrimidone compounds as pesticides |
-
2020
- 2020-05-07 WO PCT/US2020/031904 patent/WO2020227549A1/en active Application Filing
- 2020-05-07 ES ES20729390T patent/ES3020290T3/es active Active
- 2020-05-07 MX MX2021013472A patent/MX2021013472A/es unknown
- 2020-05-07 DK DK20729390.3T patent/DK3965884T3/da active
- 2020-05-07 KR KR1020217039735A patent/KR20220017917A/ko active Pending
- 2020-05-07 PH PH1/2021/552782A patent/PH12021552782A1/en unknown
- 2020-05-07 PT PT207293903T patent/PT3965884T/pt unknown
- 2020-05-07 SG SG11202111552YA patent/SG11202111552YA/en unknown
- 2020-05-07 HR HRP20250384TT patent/HRP20250384T1/hr unknown
- 2020-05-07 LT LTEPPCT/US2020/031904T patent/LT3965884T/lt unknown
- 2020-05-07 US US16/869,211 patent/US11091467B2/en active Active
- 2020-05-07 JP JP2021566558A patent/JP7574223B2/ja active Active
- 2020-05-07 BR BR112021021718A patent/BR112021021718A2/pt unknown
- 2020-05-07 CN CN202080047744.2A patent/CN114096531A/zh active Pending
- 2020-05-07 HU HUE20729390A patent/HUE070650T2/hu unknown
- 2020-05-07 GE GEAP202015821A patent/GEP20247637B/en unknown
- 2020-05-07 AU AU2020267576A patent/AU2020267576B2/en active Active
- 2020-05-07 RS RS20250336A patent/RS66686B1/sr unknown
- 2020-05-07 PE PE2021001847A patent/PE20220255A1/es unknown
- 2020-05-07 FI FIEP20729390.3T patent/FI3965884T3/fi active
- 2020-05-07 EP EP20729390.3A patent/EP3965884B1/en active Active
- 2020-05-07 PL PL20729390.3T patent/PL3965884T3/pl unknown
- 2020-05-07 EP EP24213541.6A patent/EP4523692A3/en active Pending
- 2020-05-07 CA CA3139101A patent/CA3139101A1/en active Pending
- 2020-05-07 MA MA55890A patent/MA55890B1/fr unknown
- 2020-05-07 MD MDE20220295T patent/MD3965884T2/ro unknown
- 2020-05-07 SI SI202030599T patent/SI3965884T1/sl unknown
- 2020-05-08 TW TW109115446A patent/TWI855068B/zh active
-
2021
- 2021-05-25 US US17/330,232 patent/US12180192B2/en active Active
- 2021-10-31 IL IL287720A patent/IL287720A/en unknown
- 2021-11-03 CL CL2021002883A patent/CL2021002883A1/es unknown
- 2021-11-23 CO CONC2021/0015698A patent/CO2021015698A2/es unknown
-
2024
- 2024-10-16 JP JP2024180616A patent/JP2025011262A/ja active Pending
- 2024-11-28 ZA ZA2024/09114A patent/ZA202409114B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202409114B (en) | MODULATORS OF THR-ß AND METHODS OF USE THEREOF | |
| CR20220062A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina | |
| SA520420033B1 (ar) | مركبات صيدلية | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| MX2020011501A (es) | Compuestos novedosos. | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| EP4467549A3 (en) | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives | |
| RS52823B (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| CY1117080T1 (el) | Θεραπευτικος παραγοντας για στενωση του σπονδυλικου σωληνα | |
| MX2020008570A (es) | Inhibidores de arginasa y sus metodos de uso. | |
| PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| IN2012DN02502A (es) | ||
| PH12021552513A1 (en) | Pyrrole compounds | |
| EA202092361A1 (ru) | Конъюгат цитотоксического лекарственного средства и пролекарственная форма указанного конъюгата | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| EA202092858A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2022003617A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos |